Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.53 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | P4HB | P07237 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31334693 | 0.86 | NPFFR1 (0.53) | NPFFR1NPFFR2CYP2D6P4HBCYP3A4 | |
| SCHEMBL14081425 | 0.85 | CYP2D6 (0.56) | DRD2DRD4DRD3CYP2D6CYP3A4 | |
| SCHEMBL8809190 | 0.82 | CYP3A4 (0.66) | DRD2DRD4DRD3CYP2D6P4HB | |
| SCHEMBL1269458 | 0.81 | CYP2D6 (0.61) | DRD2DRD4DRD3CYP2D6CYP3A4 | |
| SCHEMBL23538536 | 0.81 | NPFFR1 (0.50) | NPFFR1NPFFR2CYP2D6P4HBCYP3A4 | |
| SCHEMBL1997960 | 0.81 | NPFFR1 (0.58) | DRD2DRD4DRD3NPFFR1NPFFR2 | |
| SCHEMBL2146325 | 0.81 | CYP2D6 (0.49) | NPFFR1NPFFR2CYP2D6P4HBCYP3A4 | |
| SCHEMBL14722834 | 0.81 | NPFFR1 (0.50) | DRD2DRD4DRD3NPFFR1NPFFR2 | |
| SCHEMBL25590864 | 0.80 | NPFFR1 (0.49) | DRD2DRD4DRD3NPFFR1NPFFR2 | |
| SCHEMBL8479549 | 0.79 | TSHR (0.51) | NPFFR1NPFFR2CYP2D6P4HBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513110-B1 | 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| CN-102791711-A | 1, 7-diazacarbazoles and their use in the treatment of cancer | HOFFMANN LA ROCHE | 2012-11-21 | — | — | CN | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | DRD2 4854/4885DRD4 4862/4885DRD3 4814/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | DRD2 4854/4885DRD4 4862/4885DRD3 4814/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | DRD2 4854/4885DRD4 4862/4885DRD3 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.